Be part of the knowledge.™

Oncology and Hematology

838

LikeLikedUnlike

1-15 of 290

Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
CME/CE
Targeting B7-H3 in ES-SCLC: Advancing Targeted Therapy Through Evidence-Based Innovation and Multidisciplinary Care
- Taofeek K. Owonikoko, MD, PhD
  Peer
0.25 credits
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
CME/CE
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
- María-Victoria Mateos, MD, PhD
  Peer
0.25 credits
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CE
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
- Jennifer R. Brown, MD, PhD
  Peer
0.25 credits
Double-Class Refractory CLL in Community Practice: Current and Future Management
CME/CE
Double-Class Refractory CLL in Community Practice: Current and Future Management
- John C. Byrd, MD
  Peer
0.25 credits
Personalizing First-Line Therapy for CLL
CME/CE
Personalizing First-Line Therapy for CLL
- William Wierda, MD, PhD
  Peer
- Matthew S. Davids, MD, MMSc
  Peer
0.25 credits
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
CME/CE
Progress in Breast Cancer Care: Translating SABCS Data Into Practice
- Charles E. Geyer Jr., MD, FACP
  Peer
- Komal Jhaveri, MD, FACP
  Peer
0.25 credits
advertisement
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
CME/CE
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
  Peer
- Cristina Rodriguez, MD
  Peer
0.50 credits
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
CME/CE
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
- María-Victoria Mateos, MD, PhD
  Peer
- Luciano Costa, M.D., Ph.D.
  Peer
0.25 credits
MinuteCE®
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 credits 8 episodes
RAS Across Tumors: Who to Test When
MinuteCE®
RAS Across Tumors: Who to Test When
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
MinuteCE®
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
MinuteCE®
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
advertisement
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
MinuteCE®
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
- Kathryn Arbour
  Peer
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
MinuteCE®
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
- Kathryn Arbour
  Peer
0.75 program credits
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
MinuteCE®
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors 
- Eileen M. O'Reilly, MD
  Peer
0.75 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended